Table 5 Pathological complete response relative to molecular subtypes of tumor with empirical cut-offs for Ki67
From: Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
| Â | Tumor classification (+: yes/-: no) | Tumor response | Â | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | ER/PR | HER2 | Ki67 | Neoadjuvant | All | pCR no | pCR yes | Â | |||
| Â | Â | Â | Â | trastuzumab | N | % | n | % | n | % | P |
Hormone receptor-positive | + | - | ≥ 38% | NA | 53 | 100 | 43 | 81.1 | 10 | 18.9 | < 0.0001 |
| Â | + | - | < 38% | NA | 263 | 100 | 255 | 97.0 | 8 | 3.0 | Â |
|  | + or - | + | ≥ 18% | + or - | 80 | 100 | 43 | 53.7 | 37 | 46.3 | 0.02 |
HER2-positive | + or - | + | < 18% | + or - | 22 | 100 | 18 | 81.8 | 4 | 18.2 | Â |
| Â | + or - | + | + or - | + | 50 | 100 | 24 | 48.0 | 26 | 52.0 | 0.03 |
| Â | + or - | + | + or - | - | 52 | 100 | 37 | 71.2 | 15 | 28.8 | Â |
Triple negative | - | - | ≥ 35% | NA | 105 | 100 | 48 | 45.7 | 57 | 54.3 | < 0.01 |
| Â | - | - | < 35% | NA | 24 | 100 | 20 | 83.3 | 4 | 16.7 | Â |
All | + or - | + or - | + or - | + or - | 547 | 100 | 427 | 78.1 | 120 | 21.9 | Â |